Noncoverage for Anodyne Therapy?
This article was originally published in The Gray Sheet
Executive Summary
CMS proposes national non-coverage for infrared therapy devices July 26, due to insufficient evidence that the treatment is reasonable and necessary for beneficiaries with peripheral neuropathy, skin ulcers and related conditions. The agency cites poor quality, small sample size and "a significant placebo effect" in the available clinical studies. "Only when basic efficacy has been established can investigators determine through additional studies which populations, if any, might benefit from experimental light therapy," the agency writes. CMS generated the national coverage decision internally, in part due to an FDA warning letter concerning burns from the Anodyne Therapy device (1"The Gray Sheet" Feb. 6, 2006, p. 5). Comments on the proposed decision are due Aug. 25...
You may also be interested in...
In Rare Move, CMS Cites FDA Warning Letter In National Coverage Request
CMS' internally-generated national coverage request for infrared therapy devices uncharacteristically refers to a recent FDA warning letter to manufacturer Anodyne Therapy
Simplified Clinical Trial Transparency Rules To Go Live In The EU In June
A new version of the EU Clinical Trials Information System’s public portal will integrate the functionalities of the streamlined transparency rules.
Top-Selling Drugs 2023: Pharma’s $60bn COVID-19 Cliff
Pfizer/BioNTech’s COVID-19 vaccine Comirnaty toppled after recording the highest ever annual sales for a pharmaceutical in 2022, while Novo Nordisk’s Ozempic climbed rapidly. But Merck & Co’s immuno-oncology blockbuster Keytruda was secure in the number one spot in 2023 as COVID-19 receded.